Drugs / briciclib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02168725 | Jun 2014 → Dec 2015 | neoplasm | Traws Pharma, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT01049113 | Nov 2009 → Dec 2014 | acute lymphoblastic leukemia | Traws Pharma, Inc. | Terminated | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | briciclib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02168725 ↗ |
| Known as | BRICICLIB SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206245 ↗ |
| Known as | ON 013105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01049113 ↗ |
| Known as | ON 014185 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1206245 ↗ |
| Action | Inhibit | “G1/S-specific cyclin D1 inhibitor” CHEMBL1206245 ↗ |
| Modality | Small molecule | — CHEMBL1206245 ↗ |
| Route | Intravenous | “2-hour intravenous infusion once a week.” NCT01049113 ↗ |
| Target | CCND1 | “G1/S-specific cyclin D1 inhibitor” CHEMBL1206245 ↗ |